vs
Side-by-side financial comparison of HARTE HANKS INC (HHS) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $34.1M, roughly 1.2× Karyopharm Therapeutics Inc.). HARTE HANKS INC runs the higher net margin — 5.5% vs -299.9%, a 305.4% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -15.4%). Over the past eight quarters, Karyopharm Therapeutics Inc.'s revenue compounded faster (1.4% CAGR vs -6.4%).
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
HHS vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $34.1M |
| Net Profit | $2.2M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | -0.3% | -52.4% |
| Net Margin | 5.5% | -299.9% |
| Revenue YoY | -15.4% | 11.6% |
| Net Profit YoY | — | -232.0% |
| EPS (diluted) | $0.30 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $39.9M | $34.1M | ||
| Q3 25 | $39.5M | $44.0M | ||
| Q2 25 | $38.6M | $37.9M | ||
| Q1 25 | $41.6M | $30.0M | ||
| Q4 24 | $47.1M | $30.5M | ||
| Q3 24 | $47.6M | $38.8M | ||
| Q2 24 | $45.0M | $42.8M | ||
| Q1 24 | $45.4M | $33.1M |
| Q4 25 | $2.2M | $-102.2M | ||
| Q3 25 | $-2.3M | $-33.1M | ||
| Q2 25 | $-335.0K | $-37.3M | ||
| Q1 25 | $-392.0K | $-23.5M | ||
| Q4 24 | — | $-30.8M | ||
| Q3 24 | $142.0K | $-32.1M | ||
| Q2 24 | $-27.8M | $23.8M | ||
| Q1 24 | $-171.0K | $-37.4M |
| Q4 25 | -0.3% | -52.4% | ||
| Q3 25 | 1.3% | -34.6% | ||
| Q2 25 | 0.1% | -64.3% | ||
| Q1 25 | -0.1% | -110.8% | ||
| Q4 24 | -3.3% | -102.4% | ||
| Q3 24 | 4.0% | -67.8% | ||
| Q2 24 | 3.0% | -65.7% | ||
| Q1 24 | 0.8% | -101.9% |
| Q4 25 | 5.5% | -299.9% | ||
| Q3 25 | -5.8% | -75.2% | ||
| Q2 25 | -0.9% | -98.2% | ||
| Q1 25 | -0.9% | -78.2% | ||
| Q4 24 | — | -100.8% | ||
| Q3 24 | 0.3% | -82.7% | ||
| Q2 24 | -61.8% | 55.6% | ||
| Q1 24 | -0.4% | -112.8% |
| Q4 25 | $0.30 | $-7.02 | ||
| Q3 25 | $-0.31 | $-3.82 | ||
| Q2 25 | $-0.05 | $-4.32 | ||
| Q1 25 | $-0.05 | $-2.77 | ||
| Q4 24 | $-0.31 | $-2.33 | ||
| Q3 24 | $0.02 | $-3.85 | ||
| Q2 24 | $-3.84 | $-2.97 | ||
| Q1 24 | $-0.02 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.6M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.5M | $-292.9M |
| Total Assets | $91.8M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | $60.5M | ||
| Q3 25 | $6.5M | $37.7M | ||
| Q2 25 | $4.8M | $38.7M | ||
| Q1 25 | $9.0M | $38.8M | ||
| Q4 24 | $9.8M | $62.5M | ||
| Q3 24 | $5.9M | $72.8M | ||
| Q2 24 | $11.0M | $84.8M | ||
| Q1 24 | $11.5M | $30.6M |
| Q4 25 | $20.5M | $-292.9M | ||
| Q3 25 | $19.9M | $-269.3M | ||
| Q2 25 | $22.2M | $-238.9M | ||
| Q1 25 | $21.4M | $-205.9M | ||
| Q4 24 | $21.7M | $-186.0M | ||
| Q3 24 | $21.0M | $-159.6M | ||
| Q2 24 | $20.6M | $-132.1M | ||
| Q1 24 | $20.0M | $-169.0M |
| Q4 25 | $91.8M | $108.4M | ||
| Q3 25 | $92.7M | $96.2M | ||
| Q2 25 | $95.0M | $104.9M | ||
| Q1 25 | $100.6M | $127.7M | ||
| Q4 24 | $101.8M | $164.4M | ||
| Q3 24 | $108.1M | $189.5M | ||
| Q2 24 | $109.7M | $214.0M | ||
| Q1 24 | $113.4M | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $737.0K | $-11.8M |
| Free Cash FlowOCF − Capex | $-686.0K | — |
| FCF MarginFCF / Revenue | -1.7% | — |
| Capex IntensityCapex / Revenue | 3.6% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $737.0K | $-11.8M | ||
| Q3 25 | $3.2M | $-5.9M | ||
| Q2 25 | $-4.8M | $-18.7M | ||
| Q1 25 | $-818.0K | $-39.0M | ||
| Q4 24 | $4.0M | $-25.8M | ||
| Q3 24 | $-2.9M | $-19.5M | ||
| Q2 24 | $1.6M | $-38.5M | ||
| Q1 24 | $-5.7M | $-43.7M |
| Q4 25 | $-686.0K | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $-5.1M | — | ||
| Q1 25 | $-923.0K | — | ||
| Q4 24 | $3.4M | $-25.9M | ||
| Q3 24 | $-4.9M | — | ||
| Q2 24 | $926.0K | — | ||
| Q1 24 | $-6.2M | $-43.9M |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 5.5% | — | ||
| Q2 25 | -13.1% | — | ||
| Q1 25 | -2.2% | — | ||
| Q4 24 | 7.3% | -84.7% | ||
| Q3 24 | -10.2% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -13.7% | -132.6% |
| Q4 25 | 3.6% | 0.0% | ||
| Q3 25 | 2.5% | 0.0% | ||
| Q2 25 | 0.6% | 0.0% | ||
| Q1 25 | 0.3% | 0.0% | ||
| Q4 24 | 1.3% | 0.2% | ||
| Q3 24 | 4.0% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 1.2% | 0.6% |
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -20.76× | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
